Age-Specific IVF Outcomes in Infertile Women With Baseline FSH Levels ≥20 mIU/mL

Abstract

Introduction:

Infertile women with severely diminished ovarian reserve who have low birth chances with in vitro fertilization (IVF) are often denied treatment with autologous oocytes. This study was designed to determine age-specific treatment efficacy and clinical characteristics of infertile women with severely diminished ovarian reserve who had live birth following IVF with autologous oocytes.

Methods:

This retrospective cohort study investigated 291 infertile women who underwent 482 IVF cycles with autologous oocytes during 2004 to 2016 at our academically affiliated private fertility center. All women were aged <45 years and had maximum baseline follicle-stimulating hormone (FSH) levels ≥20 mIU/mL. Main outcome measures included pregnancy, spontaneous abortion, and live birth rates. Patient and treatment characteristics were compared for women who achieved a live birth to those who did not.

Results:

Live birth rates were 8.6% per treated woman and 6% per started IVF cycle. The spontaneous abortion risk was 27% per clinical pregnancy. Age-specific live birth rates were highest at 17.2% for women <35 years and lowest at 1.9% for women >42 years. Women who achieved live birth were younger than those who did not (38.0 ± 8.0 vs 40.0 ± 6.0; P = .008), had lower FSH levels (25.0 ± 20.0 vs 32.5 ± 31.0; P = .006), and produced more oocytes (3.0 ± 5.0 vs 1.0 ± 2.0; P < .001), as well as transferrable embryos (2.0 ± 2.0 vs 0.0 ± 1.0; P < .001).

Conclusion:

Infertile women up to 45 years with severely diminished ovarian reserve achieve better live birth rates than previously reported and should not be denied access to IVF based on elevated FSH levels alone.

Keywords

live birth rates IVF diminished ovarian reserve infertility

Get full access to this article

View all access options for this article.

References

Kushnir

Darmon

Shapiro

Albertini

Barad

Gleicher

. Utilization of third-party in vitro fertilization in the United States. Am J Obstet Gynecol. 2016 November 14; pii: S0002-9378(16)32019-1. doi:10.1016/j.ajog.2016.11.1022. [Epub ahead of print].

Gleicher

Kushnir

Weghofer

Barad

. The “graying” of infertility services: an impending revolution nobody is ready for. Reprod Biol Endocrinol. 2014;12:63. doi:10.1186/1477-7827-12-63.

Johnson

Patton

Titus

Battaglia

Burry

. Defining the discriminatory FSH cut off in an IVF program. Fertil Steril. 2004;81(suppl 3):18–19. doi:10.1016/j.fertnstert.2004.02.010.

Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3): e9–e17. doi:10.1016/j.fertnstert.2014.12.093.

Barad

Weghofer

Gleicher

. Utility of age-specific serum anti-Müllerian hormone concentrations. Reprod Biomed Online. 2011;22(3):284–291. doi:10.1016/j.rbmo.2010.12.002.

Barad

Weghofer

Gleicher

. Age-specific levels for basal follicle-stimulating hormone assessment of ovarian function. Obstet Gynecol. 2007;109(6):1404–1410. doi:10.1097/01.AOG.0000264065.37661.a0.

Gleicher

Weghofer

Oktay

Barad

. Do etiologies of premature ovarian aging (POA) mimic those of premature ovarian failure (POF)? Hum Reprod. 2009;24(10):2395–2400. doi:10.1093/humrep/dep256.

Gleicher

Weghofer

Barad

. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol. 2011;9:23. doi:10.1186/1477-7827-9-23.

Kaser

Goldman

Fung

Alper

Reindollar

. When is clomiphene or gonadotropin intrauterine insemination futile? Results of the Fast track and standard treatment trial and the forty and over treatment trial, two prospective randomized controlled trials. Fertil Steril. 2014;102(5):1331–1337.e1. doi:10.1016/j.fertnstert.2014.07.1239.

10.

2014 Fertility Clinic Success Rates. Assisted Reproductive Technology (ART) Report. Reproductive Health, Centers for Disease Control and Prevention. https://www.cdc.gov/art/reports/2014/fertility-clinic.html. Published September 2016. Accessed December 7, 2016.

11.

Scott

Elkind-Hirsch

Styne-Gross

Miller

Frattarelli

. The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated basal follicle-stimulating hormone. Fertil Steril. 2008;89(4):868–878. doi:10.1016/j.fertnstert.2007.03.100.

12.

Martin

Nisker

Tummon

Daniel

Auckland

Feyles

. Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels. Fertil Steril. 1996;65(6):1238–1240.

13.

Abdalla

Thum

. An elevated basal FSH reflects a quantitative rather than qualitative decline of the ovarian reserve. Hum Reprod. 2004;19(4):893–898. doi:10.1093/humrep/deh141.

14.

Ethics Committee of the American Society for Reproductive Medicine 2012. Fertility treatment when the prognosis is very poor or futile: a committee opinion. Fertil Steril. 2012;98: e6–e9.

15.

Gleicher

Weghofer

Barad

. Too old for IVF: are we discriminating against older women? J Assist Reprod Genet. 2007;24(12):639–644. doi:10.1007/s10815-007-9182-1.

16.

Gleicher

Vega

Darmon

. Live-birth rates in very poor prognosis patients, who are defined as poor responders under the Bologna criteria, with nonelective single embryo, two-embryo, and three or more embryos transferred. Fertil Steril. 2015 12; 104(6):1435–1441. doi:10.1016/j.fertnstert.2015.08.023.

17.

Gleicher

Kim

Weghofer

. Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). J Assist Reprod Genet. 2013;30(1):49–62. doi:10.1007/s10815-012-9890-z.

18.

Vega

Gleicher

Darmon

. IVF outcomes in average- and poor-prognosis infertile women according to the number of embryos transferred. Reprod Biomed Online. 2016;33(3):370–375. doi:10.1016/j.rbmo.2016.06.009.

19.

Gleicher

Darmon

Kushnir

. How FSH and AMH reflect probabilities of oocyte numbers in poor prognosis patients with small oocyte yields. Endocrine. 2016;54(2):476–483. doi:10.1007/s12020-016-1068-5.

20.

Carp

Selmi

Shoenfeld

. The autoimmune bases of infertility and pregnancy loss. J Autoimmun. 2012;38(2-3):J266–J274. doi:10.1016/j.jaut.2011.11.016.

21.

Sen

Kushnir

Barad

Gleicher

. Endocrine autoimmune diseases and female infertility. Nat Rev Endocrinol. 2014;10(1):37–50. doi:10.1038/nrendo.2013.212.

22.

Vega

Barad

. Anti-Mullerian hormone levels decline with the presence of antiphospholipid antibodies. Am J Reprod Immunol 2016;76(4):333–337. doi:10.1111/aji.12551.